Home > Oncology > Gilead drug modestly delays breast cancer progression in late-stage trial

Gilead drug modestly delays breast cancer progression in late-stage trial

Conference
ASCO 2022
Reuters - 06/06/2022 - Gilead Sciences Inc's Trodelvy extended by 1.5 months, or 34%, the length of time women with advanced stages of a common type of breast cancer lived without their disease worsening, according to trial data presented on Saturday. The Phase III study compared Trodelvy to chemotherapy in 543 patients with hormone-sensitive tumors that test negative for a receptor called HER2 and who had stopped responding to at least two earlier lines of therapy. The data, presented in Chicago at the annual meeting of the American Society of Clinical Oncology (ASCO), show progression-free survival for the Trodelvy group of 5.5 months compared with 4 months for chemotherapy patients. "Some will argue is that really a clinically meaningful difference?" Dr. Julie Gralow, ASCO's chief medical officer, told Reuters. "The real point here is we have proof of principle this drug works ... I'm sure it will be used." Trodelvy, also known as sacituzumab govite...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on